Citations

Showing 10 of 108094 citations.

Ultrasound‐guided injection of the long head of the biceps tendon sheath with concomitant subacromial bursa injection through the same needlestick
Pujalte, George G.A. , Hudspeth, Loren J., Troyer, Wesley , Pujalte, George , Troyer, Wesley D, Shapiro, Shane A.

Mayo Clinic

Clinical Anatomy | October 10, 2022 | Volume: 36 | Issue: 3 | Pages: 400-405

10.1002/ca.23961 | PMID 36210353 Get It

AbstractSonography and specific shoulder positions allow for injections into both the long head of the biceps tendon sheath (LHBTS) and the subacromial space (SS) with one needlestick. We validated this technique using cadavers. An experienced proceduralist injected latex solution into 12 unembalmed cadaveric shoulders, aiming for the LHBTS and SS, using an ultrasound‐guided injection technique that employs a single‐needle entry point. An experienced surgeon dissected each specimen and graded latex location as: (1) completely accurate (in both the SS and LHBTS); (2) partially accurate (in either the SS or LHBTS); (3) accurate with overflow (in both locations, but also elsewhere); (4) partially accurate with overflow (in either location, but also somewhere else); or (5) completely inaccurate (no latex in either location). All 12 ultrasound‐guided injections using the technique accurately placed latex into both LHBTS and SS (100% accuracy). Latex was also found in adjacent regions after two (17%) injections: one within the shoulder joint and one within the deltoid musculature. This newly described technique allows highly accurate access to the LHBTS and SS with single‐needle entry. This technique could become a favored alternative to subjecting patients to two needlesticks and preparing separate injections to address often concomitant pathologies.
Role of MIF1 / MIF2 / CD74 interactions in bladder cancer
Woolbright, Benjamin L. , Rajendran, Ganeshkumar, Abbott, Erika, Martin, Austin, Amalraj, Sarah, Dennis, Katie , Warrick, Joshua, Li, Xiaogang , Taylor, John Arthur

Mayo Clinic

The Journal of Pathology | October 10, 2022 | Volume: 259 | Issue: 1 | Pages: 46-55

10.1002/path.6018 | PMID 36214539 Get It

Abstract Macrophage migration inhibitory factor (MIF1) is a pleiotropic cytokine involved in inflammation and cancer. Genetic knockout of Mif1 in the validated N ‐butyl‐ N ‐(4‐hydroxybutyl) nitrosamine (BBN) model of bladder cancer (BCa) resulted in stage arrest at non‐muscle‐invasive disease in prior studies. Small‐molecule inhibition of MIF1 reduced cancer‐associated outcomes, but it did not fully recapitulate genetic models. D‐dopachrome tautomerase (gene symbol DDT ), commonly referred to as MIF2, is a functional homolog of MIF1, and both MIF1 and MIF2 can bind the cell surface receptor CD74 on multiple cell types to initiate a signaling cascade. It has been proposed that this interaction mediates part of the protumorigenic effects of MIF1 and MIF2 and may explain the discordance in prior studies. We hypothesized that MIF2 functions redundantly with MIF1 in BCa development and progression. The Cancer Genome Atlas (TCGA) analysis indicated MIF and DDT expression were increased in BCa patients compared to control. 4‐Iodopyridine (4‐IPP), a combined MIF1/MIF2 inhibitor, was more efficacious than ISO‐1, a MIF1‐only inhibitor, in preventing cellular proliferation in BCa cell lines. To evaluate these findings in vivo , wild‐type (WT) and Mif1 −/− animals were exposed to 0.05% BBN in drinking water for 16 weeks to initiate tumorigenesis and then evaluated over the subsequent 4 weeks for tumor formation and progression in the presence or absence of 4‐IPP. 4‐IPP reduced bladder weights in WT animals and bladder weights/tumor stage in Mif1 −/− animals. To determine whether MIF1/MIF2 functioned through CD74 in BCa, WT or Cd74 −/− animals were used in the same BBN model. Although these animals were partially protected against BBN‐induced BCa, 4‐IPP did not enhance this effect. In conclusion, our data suggest that MIF2 mechanistically functions in a similar protumorigenic manner to MIF1, and this is at least partially through CD74. Dual inhibition of MIF homologs is more efficacious at reducing tumor burden in this model of BCa. © 2022 The Pathological Society of Great Britain and Ireland.
T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
Pei, Qinglin , McCarten, Kathleen M. , Cho, Steve , Wu, Yue , Punnett, Angela , Henderson, Tara O. , Charpentier, Ann-Marie, Keller, Frank G. , Kelly, Kara M. , Castellino, Sharon M. , Parsons, Susan K. , Hodgson, David , Horton, Terzah M. , Dave, Hema , Hoppe, Bradford S.

Mayo Clinic

HemaSphere | October 10, 2022 | Volume: 6 | Issue: No issue available | Pages: 40-40

10.1097/01.hs9.0000890916.12776.84 Get It

T083: The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
Upshaw, Jenica , Nelson, Jason , Kumar, Anita J. , Klein, Andreas K. , Konstam, Marvin A. , Friedberg, Jonathan W. , Mauer, Matthew, Rodday, Angie Mae , Wong, John B. , Jaffe, Iris Zamir , Ky, Bonnie , Kent, David M. , Parsons, Susan K.

Mayo Clinic

HemaSphere | October 10, 2022 | Volume: 6 | Issue: No issue available | Pages: 38-38

10.1097/01.hs9.0000890900.69504.65 Get It

P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
Ansell, Stephen M. , Kim, Won Seog , Gallamini, Andrea , Ramchandren, Radhakrishnan , Friedberg, Jonathan W. , Eom, Hyeon‐Seok , Dong, Cassie, Campana, Frank, Fenton, Keenan , Puhlmann, Markus , Straus, David J. , Hutchings, Martin , Connors, Joseph M. , Advani, Ranjana H. , Evens, Andrew M. , Smolewski, Piotr , Savage, Kerry J. , Bartlett, Nancy L. , Abramson, Jeremy S. , Radford, John

Mayo Clinic

HemaSphere | October 10, 2022 | Volume: 6 | Issue: No issue available | Pages: 4-5

10.1097/01.hs9.0000890604.66330.a0 Get It

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
Ambinder, Richard, Cohen, Jonathon B. , David, Kevin A. , Fenske, Timothy S. , Palmisiano, Neil , Svoboda, Jakub , Ansell, Stephen M. , Diefenbach, Catherine , Jegede, Opeyemi A. , Robertson, Michael J. , Advani, Ranjana H. , Barta, Stefan K , Morgan, David , Karmali, Reem , Kahl, Brad S.

Mayo Clinic

HemaSphere | October 10, 2022 | Volume: 6 | Issue: No issue available | Pages: 46-47

10.1097/01.hs9.0000890968.53519.f4 Get It

P010: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium
Friedberg, Jonathan W. , Gallamini, Andrea , Nelson, Jason, Upshaw, Jenica , Parsons, Susan K. , Rodday, Angie Mae , Hawkes, Eliza A. , Hodgson, David M. , Johnson, Peter , Link, Brian K. , Maurer, Matthew J. , Nelson, Jason, Savage, Kerry J. , Zinzani, Pier Luigi , Evens, Andrew M.

Mayo Clinic

HemaSphere | October 10, 2022 | Volume: 6 | Issue: No issue available | Pages: 5-5

10.1097/01.hs9.0000890608.32200.eb Get It

A Call to Action to Review the USPSTF’s Recommendation for Testicular Self-Examination
Rovito, Michael J. , Allen, Keri, Nangia, Ajay K., Craycraft, Mike , Cary, Clint , Lutz, Michael, Lyon, Timothy D. , Fadich, Ana, Baird, Bryce , Welch, Morgan Garrett, Alcantara, Alexie, Lyon, Timothy, Lyon, Timothy D , Lutz, Michael

Mayo Clinic

American Journal of Men's Health | October 10, 2022 | Volume: 16 | Issue: 5 | Pages: No page available

10.1177/15579883221130186 | PMID 36214273 Get It

We urge the United States Preventive Services Task Force (USPSTF) to call for a formal review of the evidence regarding testicular self-examination (TSE). Twelve years have since passed since the evidence was last formally analyzed where normally re-reviews occur in 5-year cycles. If they would decide to move forward with this action, we ask for the USPSTF to review their methods for establishing recommendations to optimize their rating system operationalization process. Finally, emerging evidence demonstrates a net positive effect of TSE. This stands in contrast to the assertions of TSE’s supposed harm that is prevalent in the literature as well as the rationale behind the USPSTF’s “D” rating of TSE.
Community-based, Hospital-Affiliated Medical Group Becomes a Successful Accountable Care Organization
Madden, Kathleen B., DoRosario, Arnold, O’Connell, Ryan M. , Aberizk, William, Brown, Karen , Guttman, Carrie, Goldstein, Richard , Logue, Peter, Varkey, Prathibha, Madden, Kathleen, Madden, Kathleen, O’Connell, Ryan

Mayo Clinic

American Journal of Medical Quality | October 10, 2022 | Volume: 37 | Issue: 6 | Pages: 511-518

10.1097/jmq.0000000000000085 | PMID 36214586 Get It

Leadership of a multispecialty group practice within a health system recognized in 2015 that population health management requires quality performance improvement and organizational culture change. While blueprints for building successful Accountable Care Organizations (ACOs) exist in the literature, few describe the journey to achieving both shared savings and high quality outcomes achieved by a medical group within an academic health system. Clinician education and engagement, prioritizing prevention and achieving benchmarks, developing supportive roles, more precise documentation of accurate diagnostic coding, and risk stratification constituted the approach. When first participating as an ACO, the medical group built programs and teams to improve quality, while CMS simultaneously changed quality measurements from pay-for-reporting to pay-for-performance. Quality scores initially dipped, though scores have since risen to 98.44% in 2020. Between 2015 and 2017, financial results were more than $10 million below the threshold, while in performance years 2018 to 2020, Northeast Medical Group achieved $24 million in aggregate in shared savings.